The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Proksch, P.
Right arrow Articles by Li-Weber, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Proksch, P.
Right arrow Articles by Li-Weber, M.
The Journal of Immunology, 2005, 174: 7075-7084.
Copyright © 2005 by The American Association of Immunologists

Rocaglamide Derivatives Are Immunosuppressive Phytochemicals That Target NF-AT Activity in T Cells

Peter Proksch*, Marco Giaisi{dagger}, Monika K. Treiber{dagger}, Katalin Palfi{dagger}, Anette Merling{dagger}, Herbert Spring{ddagger}, Peter H. Krammer{dagger} and Min Li-Weber1,{dagger}

* Institute of Pharmaceutical Biology, University of Dusseldorf, Dusseldorf, Germany; and{dagger} Tumorimmunology Program and{ddagger} Biomedizinische Strukturforschung, German Cancer Research Center, Heidelberg, Germany

Aglaia (family Meliaceae) plants are used in traditional medicine (e.g., in Vietnam) for the treatment of inflammatory skin diseases and allergic inflammatory disorders such as asthma. Inflammatory diseases arise from inappropriate activation of the immune system, leading to abnormal expression of genes encoding inflammatory cytokines and tissue-destructive enzymes. The active compounds isolated from these plants are derivatives of rocaglamide. In this study we show that rocaglamides are potent immunosuppressive phytochemicals that suppress IFN-{gamma}, TNF-{alpha}, IL-2, and IL-4 production in peripheral blood T cells at nanomolar concentrations. We demonstrate that rocaglamides inhibit cytokine gene expression at the transcriptional level. At the doses that inhibit cytokine production, they selectively block NF-AT activity without impairing NF-{kappa}B and AP-1. We also show that inhibition of NF-AT activation by rocaglamide is mediated by strong activation of JNK and p38 kinases. Our study suggests that rocaglamide derivatives may serve as a new source of NF-AT-specific inhibitors for the treatment of certain inflammatory diseases.




This article has been cited by other articles:


Home page
BloodHome page
N. Ueffing, M. Schuster, E. Keil, K. Schulze-Osthoff, and I. Schmitz
Up-regulation of c-FLIPshort by NFAT contributes to apoptosis resistance of short-term activated T cells
Blood, August 1, 2008; 112(3): 690 - 698.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Jin, Y. Kang, L. Zhao, C. Xiao, Y. Hu, R. She, Y. Yu, X. Du, G. Zhao, T. Ng, et al.
Induction of Adaptive T Regulatory Cells That Suppress the Allergic Response by Coimmunization of DNA and Protein Vaccines
J. Immunol., April 15, 2008; 180(8): 5360 - 5372.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.